Sutro Biopharma STRO Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's accounts receivable?
- Sutro Biopharma (STRO) reported accounts receivable of $12.48M in Q1 2026.
- How has Sutro Biopharma's accounts receivable changed year-over-year?
- Sutro Biopharma's accounts receivable decreased by 7.9% year-over-year, from $13.56M to $12.48M.
- What is the long-term trend for Sutro Biopharma's accounts receivable?
- Over 5 years (2020 to 2025), Sutro Biopharma's accounts receivable has grown at a -6.5% compound annual growth rate (CAGR), from $5.56M to $3.98M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.